首页|期刊导航|中国合理用药探索|二丁酰环磷腺苷钙联合美托洛尔对心力衰竭伴心律失常的治疗效果

二丁酰环磷腺苷钙联合美托洛尔对心力衰竭伴心律失常的治疗效果OA

Therapeutic Effect of Calcium Dibutyryl Cyclic Adenosine Monophosphate Combined with Metoprolol on Heart Failure Complicated with Arrhythmia

中文摘要英文摘要

目的:探讨二丁酰环磷腺苷钙联合美托洛尔对心力衰竭(HF)伴心律失常患者的治疗效果.方法:选取 2022 年 6 月1日~2024年 9 月 30 日本院心内科收治的110 例HF伴心律失常患者,采用随机数字表法分为对照组(因依从性差剔除 2 例,n=53)和综合组(因主动退出剔除1例,n=54).两组患者均给予常规治疗,对照组给予酒石酸美托洛尔片治疗,综合组在对照组基础上联合注射用二丁酰环磷腺苷钙治疗.比较两组心功能及血管内皮功能实验室指标[N-末端脑钠肽前体(NT-proBNP)、半乳糖凝集素-3(Gal-3)、Adropin、血管性血友病因子(vWF)]、心功能超声指标[左心室射血分数(LVEF)、每搏心输出量(SV)、左心室舒张末期内径(LVEDD)]、血管内皮功能超声指标[肱动脉内皮依赖性舒张功能(FMD)、肱动脉非内皮依赖性舒张功能(NMD)]、24 h心电图参数(24 h室性早搏次数和 24 h室速发作次数)、临床疗效及不良反应发生情况.结果:治疗后,两组NT-proBNP、Gal-3、Adropin、vWF、LVEDD均降低,且综合组低于对照组(P<0.05);LVEF、SV、FMD和NMD均升高,且综合组高于对照组(P<0.05);24 h室性早搏次数和 24 h室速发作次数均减少,且综合组少于对照组(P<0.05).综合组临床治疗总有效率(92.59%)高于对照组(79.25%,P<0.05).两组不良反应总发生率比较无统计学差异(χ2=0.190,P=0.662).结论:二丁酰环磷腺苷钙联合美托洛尔可显著提高HF伴心律失常患者的临床疗效,改善心功能与血管内皮功能,且不增加不良反应的发生风险.

Objective:To explore the therapeutic effect of calcium dibutyryl cyclic adenosine monophosphate combined with metoprolol on patients with heart failure(HF)complicated with arrhythmia.Methods:From June 1,2022 to September 30,2024,110 patients with HF complicated with arrhythmia admitted to the department of cardiology of our hospital were selected and divided into the control group(2 cases excluded due to poor compliance,n=53)and the comprehensive group(1 case excluded due to active withdrawal,n=54)by random number table method.Both groups were given routine treatment.The control group was treated with metoprolol tartrate tablets,and the comprehensive group was treated with calcium dibutyryl cyclic adenosine monophosphate for injection in addition to the control group's treatment.Laboratory indicators of cardiac function and vascular endothelial function[N-terminal pro-B-type natriuretic peptide(NT-proBNP),galectin-3(Gal-3),Adropin,von Willebrand factor(vWF)],ultrasonic parameters of cardiac function[left ventricular ejection fraction(LVEF),stroke volume(SV),left ventricular end-diastolic diameter(LVEDD)],ultrasonic parameters of vascular endothelial function[flow-mediated dilation(FMD),nitroglycerin-mediated dilation(NMD)],24 h electrocardiogram parameters(24 h ventricular premature beats and 24 h ventricular tachycardia episodes),clinical efficacy and adverse reactions were compared between the two groups.Results:After treatment,NT-proBNP,Gal-3,Adropin,vWF,LVEDD decreased in both groups,and the values in the comprehensive group were lower than those in the control group(P<0.05);LVEF,SV,FMD and NMD increased in both groups,and the values in the comprehensive group were higher than those in the control group(P<0.05);the number of 24 h ventricular premature beats and the number of 24 h ventricular tachycardia episodes reduced in both groups,and the values in the comprehensive group were lower than those in the control group(P<0.05).The total clinical effective rate of the comprehensive group(92.59%)was higher than that of the control group(79.25%,P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(χ2=0.190,P=0.662).Conclusion:Calcium dibutyryl cyclic adenosine monophosphate combined with metoprolol can significantly improve the clinical efficacy of patients with HF complicated with arrhythmia,improve cardiac function and vascular endothelial function,and does not increase the risk of adverse reactions.

王东华;温保平;李华政;夏树涛;周金贵

鹤壁煤业(集团)有限责任公司总医院心内科,鹤壁 458000鹤壁煤业(集团)有限责任公司总医院心内科,鹤壁 458000鹤壁煤业(集团)有限责任公司总医院心内科,鹤壁 458000鹤壁煤业(集团)有限责任公司总医院心内科,鹤壁 458000鹤壁煤业(集团)有限责任公司总医院心内科,鹤壁 458000

医药卫生

二丁酰环磷腺苷钙美托洛尔心力衰竭心律失常心功能血管内皮功能

calcium dibutyryl cyclic adenosine monophosphatemetoprololheart failurearrhythmiacardiac functionvascular endothelial function

《中国合理用药探索》 2026 (2)

58-63,6

10.3969/j.issn.2096-3327.2026.02.007

评论